- Advance PRO1184 and PRO1160 into clinical trials
- Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms
- Build vertically integrated internal capabilities for more efficient drug development
WOODINVILLE, Wash. and SUZHOU, China, June 2, 2022 /PRNewswire/ -- ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China. Current investors Lilly Asia Ventures, Oriza, Chang'an Capital, LYFE Capital, and K2VC also participated in this round of financing. ProfoundBio has raised a total of more than $138 million in the past two years. Following the closing, Lynn Yang from Sequoia China will be joining the company's Board of Directors.
ProfoundBio will use the proceeds to advance PRO1184 and PRO1160 into Phase 1 clinical trials. PRO1184 is a folate receptor alpha (FRα)-directed ADC for potential treatment of multiple solid tumors and PRO1160 is a CD70-directed ADC for both hematological and solid tumor indications. Preclinical studies suggest that both compounds may achieve favorable benefit to risk profiles in the clinic. Additionally, the company will continue to accelerate multiple early-stage programs to preclinical and CMC development, strengthen and expand innovative ADC technologies, and establish vertically integrated development capabilities to streamline discovery to clinical trials.
"This financing, especially in the context of this challenging economic environment, represents the confidence our new and all our current investors have in our capabilities, pipeline, and ADC technology." said Baiteng Zhao, PhD, co-founder, CEO, and Chair of the Board of ProfoundBio. "We made tremendous advancements as we continue to execute on our plan to bring novel therapeutics to patients with cancer. We will soon submit an IND for PRO1184, already initiated IND-enabling activities for PRO1160, and continue to expand our pipeline. In addition, we established multiple novel ADC technology platforms as presented at the 2022 AACR annual meeting. Finally, and of equal importance, our team continues to strengthen with numerous key people identifying with and wanting to be a part of our vision."
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple candidates that are currently in discovery and preclinical development stages targeting a broad range of tumors. ProfoundBio has operations in both the greater Seattle area, WA, USA and Suzhou, China.